4/A: BiomX Inc. Director Corrects Error in Form 4 Filing Regarding Option Acquisition

Gregory Louis Merril, a director of BiomX Inc., filed an amended Form 4 to correct an administrative error in the reporting of derivative securities acquired.

Summary

• Gregory Louis Merril, a director of BiomX Inc., filed an amendment to a previously submitted Form 4.
• The amendment corrects an error in Table II, Column 5, where the number of derivative securities acquired was incorrectly reported as disposed of (D) instead of acquired (A).
• The transaction involves options to buy 17,600 shares of BiomX Inc. common stock at a price of $0.538.
• The options vest over four years, with 25% vesting on April 14, 2026, and the remainder vesting in 12 equal quarterly installments over three years.
• No other changes were made to the originally filed Form 4.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any fundamental change in the company's prospects or financial health. The sentiment is neutral to slightly positive as it shows compliance with regulations.

Industry Context

Form 4 filings are standard practice for company insiders (directors, officers, and 10% owners) to report transactions in their company's securities to the SEC, ensuring transparency and preventing insider trading.

Key Dates

Keywords

Form 4, BiomX Inc., Director, Amendment, Options, Gregory Louis Merril, Beneficial Ownership, PHGE, SEC